Mankind Pharma plans amalgamation of two subsidiaries into itself

Mergers & acquisitions
Pharmaceuticals

Blacklitt Research26 October 20262 min read

Mankind Pharma (NSE: MANKIND) approved a scheme to amalgamate two wholly owned subsidiaries, Prolijune Lifesciences Private Limited and Pavi Buildwell Private Limited, into itself, the company said in a filing on 26 Oct 2026. The company says no new shares will be issued and no consideration paid, and the scheme needs National Company Law Tribunal approval.

Key highlights

>{"label":"Appointed date","text":"01 Apr 2027 for Scheme 1"}
{"label":"Shares to be issued","text":"None, as both transferors are wholly owned subsidiaries"}
{"label":"Scheme 2","text":"Upakarma Ayurveda merging into Mankind Consumer Products"}
{"label":"Board meeting","text":"26 Oct 2026, 1:45 p.m. to 2:45 p.m. IST"}

The schemes in numbers

Item	Detail
Scheme 1 parties	Prolijune Lifesciences Private Limited and Pavi Buildwell Private Limited into Mankind Pharma Limited
Appointed date	01 Apr 2027
Consideration	None; no new equity shares issued
Scheme 2 parties	Upakarma Ayurveda Private Limited into Mankind Consumer Products Private Limited
Approvals	Shareholders and creditors where required, National Company Law Tribunal, other approvals

Scheme 1 and the group structure

The Board approved Scheme 1 under Sections 230 to 232 of the Companies Act, 2013. The company says the aim is to simplify and rationalise the group by reducing the number of legal entities. Prolijune Lifesciences is engaged in leasing buildings and real estate, and Pavi Buildwell in real estate development, according to the filing.

The filing states that Scheme 1 is exempt from a No-Objection Letter from the stock exchanges under Regulation 37(6) of the Listing Regulations, but the company will file it with the exchanges for disclosure. Scheme 1 is also a related party transaction for disclosure, the company says, although amalgamations under specific Companies Act provisions fall outside Section 188 under MCA General Circular 30/2014.

Scheme 2 and the size of the entities

The Board took note of Scheme 2, under which Upakarma Ayurveda Private Limited merges into Mankind Consumer Products Private Limited. The filing says Scheme 2 is subject to statutory and regulatory approvals as applicable.

For scale, the annexure gives the year ended 31 Mar 2026 figures: Prolijune had a turnover of ₹1.78 crore and a net worth of ₹20.62 crore, and Pavi Buildwell a net worth of minus ₹17.96 crore. Mankind Pharma reported a turnover of ₹10,421.18 crore and a net worth of ₹16,396.94 crore for the same year.

What the schemes mean for Mankind Pharma's shareholders

The company says the shareholding pattern is unchanged because no shares are issued under Scheme 1. The filing does not say when the NCLT approval or completion is expected, or what effect the schemes will have on the company's financial results.

The next step is the approval of the schemes by the required authorities, including the National Company Law Tribunal.

Reference: Original filing (PDF)

Sign up to continue reading

Create a free account to read the rest of this article and the analysis that follows.

Disclaimer:

The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.